{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:29:37Z","timestamp":1791844177034,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian Pediatr"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13312-026-00333-4","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:11:02Z","timestamp":1776082262000},"page":"589-593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Democratizing the Cure: Indigenous Innovations and the Future of Pediatric Cell and Gene Therapy in India"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7693-1678","authenticated-orcid":false,"given":"Prasad","family":"Iyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2500-9936","authenticated-orcid":false,"given":"Rajat","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2181-1825","authenticated-orcid":false,"given":"Gaurav","family":"Kharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"333_CR1","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jcyt.2025.01.017","volume":"27","author":"WYK Hwang","year":"2025","unstructured":"Hwang WYK, Muzammil EM. The current state of cytotherapy and the field of cell and gene therapy. Cytotherapy. 2025;27:678\u201385.","journal-title":"Cytotherapy"},{"key":"333_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, et al. Three-year update of Tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial. J Clin Oncol. 2023;41:1664\u20139.","journal-title":"J Clin Oncol"},{"key":"333_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00134-024-07576-4","volume":"50","author":"T Schroeder","year":"2024","unstructured":"Schroeder T, Martens T, Fransecky L, et al. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities. Intensive Care Med. 2024;50:1459\u201369.","journal-title":"Intensive Care Med"},{"key":"333_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2024.101678","volume":"28","author":"P Rao","year":"2024","unstructured":"Rao P, Raj EA, Natesan S, Gudi N. Prevalence of sickle cell disease, sickle cell trait and HBS-beta-thalassemia in India: a systematic review and meta-analysis. Clin Epidemiol Glob Health. 2024;28:101678.","journal-title":"Clin Epidemiol Glob Health"},{"key":"333_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.phoj.2017.10.002","volume":"2","author":"R Colah","year":"2017","unstructured":"Colah R, Italia K, Gorakshakar A. Burden of thalassemia in India: the road map for control. Pediatr Hematol Oncol J. 2017;2:79\u201384.","journal-title":"Pediatr Hematol Oncol J"},{"key":"333_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322.","journal-title":"N Engl J Med"},{"key":"333_CR7","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1056\/NEJMe2505721","volume":"392","author":"AL Gropman","year":"2025","unstructured":"Gropman AL, Komor AC. Personalized gene editing to treat an inborn error of metabolism. N Engl J Med. 2025;392:2273\u20136.","journal-title":"N Engl J Med"},{"key":"333_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41408-025-01279-9","volume":"15","author":"G Narula","year":"2025","unstructured":"Narula G, Keerthivasagam S, Jain H, et al. Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel\u2122) cells in relapsed\/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I\/Ib study. Blood Cancer J. 2025;15:75.","journal-title":"Blood Cancer J"},{"key":"333_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200977","volume":"33","author":"HK Palani","year":"2025","unstructured":"Palani HK, Arunachalam AK, Kulkarni U, et al. Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial. Mol Ther Oncol. 2025;33:200977.","journal-title":"Mol Ther Oncol"},{"key":"333_CR10","doi-asserted-by":"publisher","unstructured":"Ansari MS, Chauhan V, Akhtar A, et al. AI-guided design and AKT3 degradation synergize to enhance bispecific and trispecific CAR-T cell persistence and overcome antigen escape. bioRxiv; 2025. Accessed on Dec 9, 2025. Available from: https:\/\/doi.org\/10.1101\/2025.06.12.658477","DOI":"10.1101\/2025.06.12.658477"},{"key":"333_CR11","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s00277-023-05457-2","volume":"103","author":"AM Alayoubi","year":"2024","unstructured":"Alayoubi AM, Khawaji ZY, Mohammed MA, Mercier FE. CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia. Ann Hematol. 2024;103:1805\u201317.","journal-title":"Ann Hematol"},{"key":"333_CR12","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","volume":"392","author":"K Musunuru","year":"2025","unstructured":"Musunuru K, Grandinette SA, Wang X, et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med. 2025;392:2235\u201343.","journal-title":"N Engl J Med"},{"key":"333_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1056\/NEJMoa2410597","volume":"392","author":"A Srivastava","year":"2025","unstructured":"Srivastava A, Abraham A, Aboobacker F, et al. Lentiviral gene therapy with CD34+ hemophilia A. N Engl J Med. 2025;392:450\u20137.","journal-title":"N Engl J Med"},{"key":"333_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/picr.PICR_189_20","volume":"12","author":"K Sivagourounadin","year":"2021","unstructured":"Sivagourounadin K, Ravichandran M, Rajendran P. National guidelines for gene therapy product (2019): a road-map to gene therapy products development and clinical trials. Perspect Clin Res. 2021;12:118\u201325.","journal-title":"Perspect Clin Res"},{"key":"333_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/picr.picr_244_22","volume":"15","author":"V Dalal","year":"2024","unstructured":"Dalal V, Jotwani G, Yadav ML. Redefining informed consent form in cell and gene therapy trials. Perspect Clin Res. 2024;15:4\u20139.","journal-title":"Perspect Clin Res"}],"container-title":["Indian Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-026-00333-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13312-026-00333-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-026-00333-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:16:28Z","timestamp":1785518188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13312-026-00333-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1007\/s13312-026-00333-4","relation":{},"ISSN":["0019-6061","0974-7559"],"issn-type":[{"value":"0019-6061","type":"print"},{"value":"0974-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Generative AI tools were used solely for linguistic refinement and structural editing during the preparation of this manuscript; all intellectual content and final interpretations remain the responsibility of the authors. Figure\n                      \n                      was produced using AI-assisted graphic tools based on original \nconceptual designs developed by the authors.","order":2,"name":"Ethics","label":"Use of Artificial Intelligence (AI) Tools During Manuscript Writing","group":{"name":"EthicsHeading","label":"Ethics"}}]}}